

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:07:08 ON 29 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-308-4498  
jan.delaval@uspto.gov

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0  
DICTIONARY FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot l41

L41 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 415678-15-8 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[4-(1H-imidazol-4-ylmethyl)phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H21 N5 O3  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

L41 ANSWER 2 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 415678-14-7 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, N-[(3,5-difluorophenyl)methyl]-6-ethoxy-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H15 F2 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

L41 ANSWER 3 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **304680-79-3** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H19 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

L41 ANSWER 4 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220861-17-6** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[3-[(methylamino)methyl]phenyl]methyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

MF C20 H22 N4 O3 . Cl H

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CRN (304680-89-5)



● HCl

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 5 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-95-7 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[[4-[(methylamino)methyl]phenyl]methyl]-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H22 N4 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 6 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-93-5 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-(dimethylamino)-1,4-dihydro-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H16 N4 O2 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 7 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-92-4** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-(4-morpholinyl)-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H18 N4 O3 S

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225


REFERENCE 4: 130:196645

L41 ANSWER 8 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-90-2** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-(2-methoxyethoxy)-4-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD  
MF C17 H17 N3 O4 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 9 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-81-1 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(4-methylphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C19 H19 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972


REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 10 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-75-3 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(4-

methoxyphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C19 H19 N3 O4  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 11 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-74-2 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-[(4-fluorophenyl)methyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H16 F N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 12 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-72-0 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-[(2-fluorophenyl)methyl]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H16 F N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 13 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-70-8 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C16 H15 N3 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 14 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-68-4 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(1H-imidazol-4-ylmethyl)-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C15 H15 N5 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 15 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-67-3 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C17 H14 F N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972



REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 16 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-66-2** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-[(3-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H14 F N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 17 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-65-1** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-[(2-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H14 F N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 18 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-64-0** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 1,4-dihydro-6-methoxy-4-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H15 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)

4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 19 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-62-8** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(5-hydroxypentyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 20 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-60-6 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 21 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-59-3 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-N-(3-ethoxypropyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 22 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-58-2 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-[(3-methoxyphenyl)methyl]-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C19 H19 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 23 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-56-0 REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-N-(3-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 24 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-52-6** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C17 H21 N3 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

L41 ANSWER 25 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-50-4** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C18 H17 N3 O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 26 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-48-0** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-pentyl-  
(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H21 N3 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225


REFERENCE 4: 130:196645

L41 ANSWER 27 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-47-9** REGISTRY

CN 1,5-Naphthyridine-3-carboxamide, N-butyl-6-ethoxy-1,4-dihydro-4-oxo- (9CI)  
(CA INDEX NAME)

FS 3D CONCORD  
MF C15 H19 N3 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 28 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN **220860-45-7** REGISTRY


CN 1,5-Naphthyridine-3-carboxamide, N-butyl-6-chloro-1,4-dihydro-4-oxo- (9CI)  
(CA INDEX NAME)

FS 3D CONCORD

MF C13 H14 Cl N3 O2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1957 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972


REFERENCE 2: 136:319416

REFERENCE 3: 133:335225

REFERENCE 4: 130:196645

L41 ANSWER 29 OF 31 REGISTRY COPYRIGHT 2003 ACS

RN 220860-44-6 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)-, monopotassium salt (9CI) (CA INDEX NAME)  
MF C18 H17 N3 O3 . K  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
CRN (220860-50-4)




● K

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:335225

REFERENCE 2: 130:196645

L41 ANSWER 30 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-43-5 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, 6-ethoxy-1,4-dihydro-4-oxo-N-(phenylmethyl)-, monosodium salt (9CI) (CA INDEX NAME)  
MF C18 H17 N3 O3 . Na  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
CRN (220860-50-4)



● Na

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 133:335225

REFERENCE 2: 130:196645

L41 ANSWER 31 OF 31 REGISTRY COPYRIGHT 2003 ACS  
RN 220860-40-2 REGISTRY  
CN 1,5-Naphthyridine-3-carboxamide, N-[2-(ethylthio)ethyl]-1,4-dihydro-6-methoxy-4-oxo- (9CI) (CA INDEX NAME)



FS 3D CONCORD  
 MF C14 H17 N3 O3 S  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:210972

REFERENCE 2: 136:319416

REFERENCE 3: 130:196645

=> d ide can tot 138

L38 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 415973-05-6 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[(1R)-1-(dimethylamino)ethyl]phenyl  
 ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN SDZ 212712


FS STEREOSEARCH

MF C14 H22 N2 O2

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:335150

L38 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 145508-78-7 REGISTRY

CN 6H-Pyrrolo[3,2-f]-1,2-benzisoxazol-6-one, 5,7-dihydro-3-[2-[1-

(phenylmethyl)-4-piperidinyloxyethyl]- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN CP 118954

CN **Icopezil**

FS 3D CONCORD


MF C23 H25 N3 O2

CI COM

SR CA

LC STN Files: ADISNEWS, BIOSIS, CA, CAPLUS, CASREACT, DDFU, DRUGNL,  
DRUGPAT, DRUGU, DRUGUPDATES, IPA, SYNTHLINE, TOXCENTER, USAN, USPAT2,  
USPATFULL

Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1957 TO DATE)

19 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:149611

REFERENCE 2: 136:350581

REFERENCE 3: 136:319416

REFERENCE 4: 136:145265

REFERENCE 5: 135:339282

REFERENCE 6: 135:251415

REFERENCE 7: 133:344629

REFERENCE 8: 133:331554

REFERENCE 9: 132:329435

REFERENCE 10: 132:132346

L38 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 130791-77-4 REGISTRY

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5S,9S,11E)- (9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, [5S-(5.alpha.,9.beta.,11E)]-

## OTHER NAMES:

CN **(+)-Huperzine A**

CN (+)-Selagine


FS STEREOSEARCH

MF C15 H18 N2 O

SR CA

LC STN Files: ADISINSIGHT, AGRICOLA, BEILSTEIN\*, BIOSIS, CA, CAPLUS,  
CASREACT, CHEMINFORMRX, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

15 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:259310  
REFERENCE 2: 136:319270  
REFERENCE 3: 136:161385  
REFERENCE 4: 134:172932  
REFERENCE 5: 133:105191  
REFERENCE 6: 132:347771  
REFERENCE 7: 132:166372  
REFERENCE 8: 131:310755  
REFERENCE 9: 129:28115  
REFERENCE 10: 124:306513

L38 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 123441-03-2 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl  
ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester,  
(S)-

OTHER NAMES:

CN ENA 713 free base

CN Exelon

CN Rivastigmine

CN SDZ 212-713

FS STEREOSEARCH

MF C14 H22 N2 O2

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, IPA, MEDLINE, MRCK\*, PHAR, PHARMASEARCH, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

117 REFERENCES IN FILE CA (1957 TO DATE)

2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

118 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248345

REFERENCE 2: 138:231759

REFERENCE 3: 138:200816

REFERENCE 4: 138:198432

REFERENCE 5: 138:180503

REFERENCE 6: 138:163577

REFERENCE 7: 138:147558

REFERENCE 8: 138:117580

REFERENCE 9: 138:65959

REFERENCE 10: 138:49850

L38 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 120014-06-4 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-E 2020

CN Donepezil

FS 3D CONCORD

DR 142057-79-2

MF C24 H29 N O3

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK\*, MSDS-OHS, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2,

## USPATFULL

(\*File contains numerically searchable property data)

Other Sources: WHO



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

217 REFERENCES IN FILE CA (1957 TO DATE)

6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

217 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:265145

REFERENCE 2: 138:248536

REFERENCE 3: 138:248535

REFERENCE 4: 138:248354

REFERENCE 5: 138:231759

REFERENCE 6: 138:231296

REFERENCE 7: 138:147599

REFERENCE 8: 138:130980

REFERENCE 9: 138:100818

REFERENCE 10: 138:83269

L38 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 120011-70-3 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Aricept

CN BNAG

CN Donepezil hydrochloride

CN E 2020

CN E 2020 (pharmaceutical)

DR 142057-77-0


MF C24 H29 N O3 . Cl H

SR CA

LC STN Files: ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DIOGENES, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PHARMASEARCH, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

CRN (120014-06-4)



● HCl

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

161 REFERENCES IN FILE CA (1957 TO DATE)  
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 164 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248536

REFERENCE 2: 138:248535

REFERENCE 3: 138:163577

REFERENCE 4: 138:119337

REFERENCE 5: 138:100847

REFERENCE 6: 138:61310

REFERENCE 7: 138:33350

REFERENCE 8: 138:32709

REFERENCE 9: 138:11346

REFERENCE 10: 138:350

L38 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 105601-20-5 REGISTRY

CN Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester  
 (9CI) (CA INDEX NAME)

FS 3D CONCORD

DR 129101-52-6


MF C14 H22 N2 O2

CI COM

SR CA

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, DRUGPAT, DRUGUPDATES,  
 TOXCENTER, USPATFULL

(\*File contains numerically searchable property data)



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:55734  
REFERENCE 2: 136:183572  
REFERENCE 3: 134:305320  
REFERENCE 4: 106:188457  
REFERENCE 5: 106:4687

L38 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 102518-79-6 REGISTRY

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, (5R,9R,11E)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5,9-Methanocycloocta[b]pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-, [5R-(5.alpha.,9.beta.,11E)]-

CN Selagine (6CI, 8CI)

OTHER NAMES:

CN (-)-Huperzine A

CN (-)-Isoselagine

CN (-)-Selagine

CN Huperzine A

CN Isoselagine

CN Kimpukan A

FS STEREOSEARCH

DR 116-28-9, 1369-64-8, 92138-20-0

MF C15 H18 N2 O

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, NAPRALERT, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry as shown.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

218 REFERENCES IN FILE CA (1957 TO DATE)  
23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
220 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:248348  
REFERENCE 2: 138:231596  
REFERENCE 3: 138:210049  
REFERENCE 4: 138:182260  
REFERENCE 5: 138:163573  
REFERENCE 6: 138:112410  
REFERENCE 7: 138:8355  
REFERENCE 8: 137:332983  
REFERENCE 9: 137:316111  
REFERENCE 10: 137:305894

L38 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 60384-53-4 REGISTRY

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aR,6S,8aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Galanthamine, (3.alpha.,4a.beta.,12a.beta.)-

OTHER NAMES:

CN **(+)-Galanthamine**

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aR-(4a.alpha.,6.beta.,8aR\*)]-

CN ent-Galanthamine


FS STEREOSEARCH

MF C17 H21 N O3

CI COM

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

15 REFERENCES IN FILE CA (1957 TO DATE)



## 15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:237232  
REFERENCE 2: 132:93500  
REFERENCE 3: 131:149380  
REFERENCE 4: 128:13368  
REFERENCE 5: 127:135980  
REFERENCE 6: 126:8355  
REFERENCE 7: 125:196086  
REFERENCE 8: 125:114933  
REFERENCE 9: 123:112051  
REFERENCE 10: 122:240093

L38 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 29347-10-2 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aR,8aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4.alpha.,12.alpha.-Physostigmine (8CI)

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aR-cis)-

OTHER NAMES:

CN **(+)-Physostigmine**

FS STEREOSEARCH


MF C15 H21 N3 O2

CI COM

LC STN Files: BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CAPLUS, GMELIN\*, IPA, NAPRALERT, TOXCENTER, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1957 TO DATE)

20 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:251277  
REFERENCE 2: 131:19172  
REFERENCE 3: 129:149126

REFERENCE 4: 127:162007  
REFERENCE 5: 125:114929  
REFERENCE 6: 124:33165  
REFERENCE 7: 123:47400  
REFERENCE 8: 122:255432  
REFERENCE 9: 121:109333  
REFERENCE 10: 120:134893

L38 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 357-70-0 REGISTRY

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl- (7CI)

CN Galanthamine (6CI, 8CI)

OTHER NAMES:

CN (-)-Galanthamine

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4aS-(4a.alpha.,6.beta.,8aR\*)]-

CN Galantamin

CN **Galantamine**

CN Jilkon

CN Lycoremin

CN Lycoremine

CN [4aS-(4a.alpha.,6.beta.,8aR\*)]-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol

FS STEREOSEARCH

DR 736-79-8, 1551-02-6

MF C17 H21 N O3


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HODOC\*, IPA, MEDLINE, MRCK\*, NAPRALERT, PHAR, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

577 REFERENCES IN FILE CA (1957 TO DATE)  
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
580 REFERENCES IN FILE CAPLUS (1957 TO DATE)  
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:231759  
REFERENCE 2: 138:226433  
REFERENCE 3: 138:217351  
REFERENCE 4: 138:187161  
REFERENCE 5: 138:165922  
REFERENCE 6: 138:163577  
REFERENCE 7: 138:137102  
REFERENCE 8: 138:126979  
REFERENCE 9: 138:89944  
REFERENCE 10: 138:66100

L38 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 321-64-2 REGISTRY

CN 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acridine, 9-amino-1,2,3,4-tetrahydro- (7CI, 8CI)

CN Acridine, 9-aminotetrahydro- (6CI)

OTHER NAMES:

CN 1,2,3,4-Tetrahydro-9-acridinamine

CN 1,2,3,4-Tetrahydro-9-aminoacridine

CN 9-Amino-1,2,3,4-tetrahydroacridine

CN Tacrine

CN Tetrahydroaminacrine

CN Tetrahydroaminocrin

CN Tetrahydroaminocrine

CN THA


MF C13 H14 N2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,  
CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES,  
DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR,  
PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

984 REFERENCES IN FILE CA (1957 TO DATE)  
46 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
987 REFERENCES IN FILE CAPLUS (1957 TO DATE)  
24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:265139  
REFERENCE 2: 138:250076  
REFERENCE 3: 138:248481  
REFERENCE 4: 138:231759  
REFERENCE 5: 138:231651  
REFERENCE 6: 138:226547  
REFERENCE 7: 138:216760  
REFERENCE 8: 138:205824  
REFERENCE 9: 138:182260  
REFERENCE 10: 138:182123

L38 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 57-47-6 REGISTRY

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,  
methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Physostigmine (8CI)**

CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,  
methylcarbamate (ester), (3aS-cis)-

OTHER NAMES:

CN (-)-Eserine

CN (-)-Physostigmine

CN Cogmine

CN Eserine

CN Esromiotin

CN MCV 4484

CN NIH 10421

CN Physostol

FS STEREOSEARCH

DR 511-49-9; 50975-37-6

MF C15 H21 N3 O2

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,  
CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE,  
GMELIN\*, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS\*, SPECINFO,  
SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3056 REFERENCES IN FILE CA (1957 TO DATE)  
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
3059 REFERENCES IN FILE CAPLUS (1957 TO DATE)  
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:265053

REFERENCE 2: 138:200816

REFERENCE 3: 138:199058

REFERENCE 4: 138:198554

REFERENCE 5: 138:180962

REFERENCE 6: 138:180572

REFERENCE 7: 138:163213

REFERENCE 8: 138:148863

REFERENCE 9: 138:147175

REFERENCE 10: 138:142332

L38 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 52-68-6 REGISTRY

CN Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN (+-)-Trichlorfon

CN 1-Hydroxy-2,2,2-trichloroethylphosphonate-O,O-dimethyl ester

CN Aerol 1 (pesticide)

CN Agroforotox

CN Anthon

CN BAY-a 9826

CN BAY-L 1359

CN Bayer L 13/59

CN Bayer L 1359

CN Chlorak

CN Chlorofos

CN Chloroftalm

CN Chlorophos

CN Chlorophthalm  
 CN Chloroxyphos  
 CN Combot  
 CN Danex  
 CN DEP  
 CN DEP (pesticide)  
 CN Depthon  
 CN DETF  
 CN Dimethyl (2,2,2-trichloro-1-hydroxyethyl)phosphonate  
 CN Dimethyl 1-hydroxy-2,2,2-trichloroethylphosphonate  
 CN Dimetox  
 CN Dioxaphos  
 CN Dipterex  
 CN Dipterex 50  
 CN Dipterex 500  
 CN Dipterex SL  
 CN Dipterex WP. 80  
 CN Diptevur  
 CN Ditrifon  
 CN Ditriphon 50  
 CN Dylox  
 CN Dyrex  
 CN Dyvon  
 CN ENT 19,763  
 CN Flibol E  
 CN Fliegenteller  
 CN Forotox  
 CN Foschlor  
 CN Foschlor R  
 CN Foschlor R 50  
 CN Hypodermacid  
 CN Loisol  
 CN Masoten  
 CN Mazoten  
 CN Methyl chlorophos  
 CN **Metrifonate**  
 CN Metriphonate

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY


FS 3D CONCORD  
 DR 56042-25-2, 66758-31-4, 50924-44-2, 37333-09-8  
 MF C4 H8 Cl3 O4 P  
 CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,  
 CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*,  
 DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB\*, IFICDB,  
 IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR,  
 PHARMASEARCH, PIRA, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER,  
 ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5141 REFERENCES IN FILE CA (1957 TO DATE)  
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
5144 REFERENCES IN FILE CAPLUS (1957 TO DATE)  
297 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:267208  
REFERENCE 2: 138:267201  
REFERENCE 3: 138:251130  
REFERENCE 4: 138:233389  
REFERENCE 5: 138:233382  
REFERENCE 6: 138:231759  
REFERENCE 7: 138:223306  
REFERENCE 8: 138:200332  
REFERENCE 9: 138:200331  
REFERENCE 10: 138:200308

=> d ide can 19

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 9000-81-1 REGISTRY

CN Esterase, acetyl choline (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Acetyl .beta.-methylcholinesterase

CN Acetylcholine acetylhydrolase

CN Acetylcholine esterase

CN Acetylcholine hydrolase

CN Acetylcholinesterase

CN Acetylthiocholinesterase

CN E.C. 3.1.1.7

DR 9026-02-2

MF Unspecified

CI MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,  
CSCHEM, CSNB, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS,  
NIOSHTIC, PROMT, TOXCENTER, ULIDAT, USPAT2, USPATFULL

Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

## \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

16319 REFERENCES IN FILE CA (1957 TO DATE)  
187 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
16335 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:268006  
REFERENCE 2: 138:267525  
REFERENCE 3: 138:267067  
REFERENCE 4: 138:267066

REFERENCE 5: 138:265813  
REFERENCE 6: 138:265139  
REFERENCE 7: 138:265036  
REFERENCE 8: 138:264963  
REFERENCE 9: 138:255460  
REFERENCE 10: 138:253331

=> d ide can l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 56-12-2 REGISTRY

CN Butanoic acid, 4-amino- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butyric acid, 4-amino- (7CI, 8CI)

OTHER NAMES:

CN .gamma.-Aminobutanoic acid

CN .gamma.-Aminobutyric acid

CN .gamma.-Aminobutyric acid

CN .omega.-Aminobutyric acid

CN 3-Carboxypropylamine

CN 4-Aminobutanoic acid

CN 4-Aminobutyric acid

CN Aminalton

CN GABA

CN Gaballon

CN Gamarex

CN Gammalon

CN Gammalone

CN Gammar

CN Gammasol

CN Mielogen

CN Mielomade

CN Piperidic acid

CN Piperidinic acid

FS 3D CONCORD

DR 3131-86-0

MF C4 H9 N O2

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM\*, DRUGU, EMBASE, GMELIN\*, HODOC\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

$\text{H}_2\text{N}-(\text{CH}_2)_3-\text{CO}_2\text{H}$

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

24700 REFERENCES IN FILE CA (1957 TO DATE)



427 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
24727 REFERENCES IN FILE CAPLUS (1957 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:276296  
REFERENCE 2: 138:270633  
REFERENCE 3: 138:270445  
REFERENCE 4: 138:268682  
REFERENCE 5: 138:268275  
REFERENCE 6: 138:265970  
REFERENCE 7: 138:265959  
REFERENCE 8: 138:265958  
REFERENCE 9: 138:265954  
REFERENCE 10: 138:265942

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:09:24 ON 29 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Apr 2003 VOL 138 ISS 18  
FILE LAST UPDATED: 28 Apr 2003 (20030428/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot 148

L48 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS  
AN 2002:695763 HCAPLUS  
DN 137:210972  
TI Use of **GABAA** inverse agonists in combination with nicotine  
receptor partial agonists, estrogen, selective estrogen modulators, or  
vitamin E for the treatment of cognitive disorders  
IN **Villalobos, Anabella**  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DT Patent  
LA English

IC ICM A61K031-00  
ICS C07D471-04; A61P025-28  
CC 1-11 (Pharmacology)  
Section cross-reference(s): 2, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069948	A1	20020912	WO 2002-IB515	20020220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002193360	A1	20021219	US 2002-83743	20020226
PRAI	US 2001-272566P	P	20010301		
OS	MARPAT 137:210972				
AB	<p>A pharmaceutical compn. and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a <b>GABAA</b> inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The <b>GABAA</b> inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amts. that render the compn. effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment assocd. with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS assocd. dementia and attention deficit disorder. The method of using these compns. is also disclosed.</p>				
ST	cognitive disorder treatment <b>GABAA</b> inverse agonist combination;				
IT	nicotine receptor partial agonist combination cognitive disorder treatment				
IT	<b>GABA</b> agonists (GABAA, inverse agonists; use of <b>GABAA</b> inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	<b>GABA</b> receptors RL: BSU (Biological study, unclassified); BIOL (Biological study) (GABAA, .alpha.5 subtype; use of <b>GABAA</b> inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Drug delivery systems (carriers; use of <b>GABAA</b> inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Mental disorder (cognitive; use of <b>GABAA</b> inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Cognition (disorder; use of <b>GABAA</b> inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)				
IT	Estrogen receptors RL: BSU (Biological study, unclassified); BIOL (Biological study)				

(modulators; use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Nicotinic agonists  
(partial; use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Cognition enhancers  
Drug interactions  
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT Nicotinic receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders).

IT Estrogens  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

IT 1406-18-4, Vitamin E 69718-72-5 207391-08-0 207391-10-4  
207391-12-6 207391-15-9 207391-18-2 207391-21-7 207391-24-0  
207391-27-3 207391-28-4 207391-29-5 207391-34-2 207391-36-4  
207391-37-5 207391-38-6 207391-39-7 207391-40-0 207391-41-1  
207391-42-2 207391-44-4 207391-63-7 207391-64-8 207391-65-9  
207391-67-1 207391-74-0 220860-40-2 220860-45-7  
220860-47-9 220860-48-0 220860-50-4  
220860-52-6 220860-56-0 220860-58-2  
220860-59-3 220860-60-6 220860-62-8  
220860-64-0 220860-65-1 220860-66-2  
220860-67-3 220860-68-4 220860-70-8  
220860-72-0 220860-74-2 220860-75-3  
220860-81-1 220860-90-2 220860-92-4  
220860-93-5 220860-95-7 220861-17-6  
248275-68-5 248275-79-8 248275-81-2 248275-95-8 248276-19-9  
249296-44-4 287973-23-3 287973-26-6 287973-27-7 304680-79-3  
328055-77-2 328055-78-3 328055-79-4 328055-80-7 328055-81-8  
328055-84-1 328055-85-2 328055-86-3 328055-87-4 328055-88-5  
328055-89-6 328055-90-9 328055-92-1 328055-94-3 328055-95-4  
328055-96-5 328055-97-6 328055-99-8 328056-00-4 328056-01-5  
328056-02-6 328056-03-7 328056-04-8 328056-05-9 328056-06-0  
328056-07-1 328056-08-2 328056-09-3 328056-10-6 328056-11-7  
328056-12-8 328056-13-9 328056-14-0 328056-15-1 328056-21-9  
328056-22-0 328056-23-1 328056-24-2 328056-25-3 328056-26-4  
328056-27-5 328056-28-6 328056-29-7 328056-30-0 328056-66-2  
357424-19-2 367511-27-1 367511-30-6 367511-38-4 415678-14-7  
415678-15-8 457634-09-2 457634-13-8 457634-14-9  
457634-15-0 457634-16-1 457634-17-2  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of **GABAA** inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Desimone, R; WO 9910347 A 1999 HCAPLUS
- (2) Neurogen Corp; WO 0071528 A 2000 HCAPLUS

DN 136:319416  
 TI Combination of **acetylcholinesterase** inhibitors and **GABAA**  
 inverse agonists for the treatment of cognitive disorders  
 IN Villalobos, Anabella; Cassella, James Vincent;  
 Rajachandran, Lavanya  
 PA Pfizer Products Inc., USA; Neurogen Corporation  
 SO PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-00  
 CC 1-11 (Pharmacology)  
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032412	A2	20020425	WO 2001-IB1934	20011015
	WO 2002032412	A3	20030320		
	W:	AE, AG, AL, AM, <del>AT</del> , AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, <del>IN</del> , IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002151591	A1	20021017	US 2001-976347	20011012
	AU 2001094117	A5	20020429	AU 2001-94117	20011015
PRAI	US 2000-241145P	P	20001017		
	WO 2001-IB1934	W	20011015		
OS	MARPAT 136:319416				
GI					



AB This invention provides a compn. for treating a cognitive disorder, which comprises an **acetylcholinesterase**, and a **GABAA** inverse agonist selected from a compd. (I, where X = e.g., H, halo, Ph, naphthyl, pyridinyl; Y = e.g., C1-8 alkyl, carbocycle). Thus, **aricept** and a **GABAA** inverse agonist (e.g., N-benzyl-6-ethoxy-4-oxo-1,4-tetrahydro-1,5-naphthyridine-3-carboxamide), when coadministered, interact to attenuate scopolamine-induced deficits in the spatial water maze.

ST **acetylcholinesterase** inhibitor **GABAA** agonist cognitive enhancer; **aricept** tetrahydronaphthyridinecarboxamide cognitive enhancer


IT **GABA** agonists  
 (GABAA; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)

IT Mental disorder  
 (attention deficit disorder; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)

- IT Mental disorder  
(cognitive; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Anti-Alzheimer's agents  
Antiparkinsonian agents  
Cognition enhancers  
Down's syndrome  
Drug delivery systems  
Memory, biological  
Psychotropics  
(combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Mental disorder  
(dementia, vascular; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Cognition  
(disorder; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Drug delivery systems  
(prodrugs; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Brain, disease  
(stroke; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Drug interactions  
(synergistic; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT Brain, disease  
(trauma; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT 52-68-6, Metrifonate 57-47-6,  
Physostigmine 321-64-2, Tacrine  
357-70-0, Galantamine 102518-79-6,  
Huperzine A 120011-70-3, Aricept  
123441-03-2, Rivastigmine 145508-78-7,  
Icopezil 220860-40-2 220860-45-7  
220860-47-9 220860-48-0 220860-50-4  
220860-52-6 220860-56-0 220860-58-2  
220860-59-3 220860-60-6 220860-62-8  
220860-64-0 220860-65-1 220860-66-2  
220860-67-3 220860-68-4 220860-70-8  
220860-72-0 220860-74-2 220860-75-3  
220860-81-1 220860-90-2 220860-92-4  
220860-93-5 220860-95-7 220861-17-6  
304680-79-3 415678-14-7 415678-15-8  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- IT 9000-81-1, **Acetylcholinesterase**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; combination of **acetylcholinesterase** inhibitors and **GABAA** inverse agonists for treatment of cognitive disorders)
- L48 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS  
AN 2000:785902 HCAPLUS  
DN 133:335225  
TI Substituted 4-oxo-naphthyridine-3-carboxamides: **GABA** brain  
receptor ligands

IN Albaugh, Pamela A.; Desimone, Robert W.; Liu, Gang  
 PA Neurogen Corp., USA  
 SO U.S., 27 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K031-44  
 ICS C07D471-02  
 NCL 514300000  
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6143760	A	20001107	US 1998-139456	19980825
	ZA 9807957	A	20000322	ZA 1998-7957	19980901
	US 6399604	B1	20020604	US 2000-634093	20000808
	US 2002156280	A1	20021024	US 2002-114743	20020402
PRAI	US 1997-56799P	P	19970825		
	US 1998-139456	A1	19980825		
	US 2000-634093	A1	20000808		
OS	MARPAT 133:335225				
GI					



AB The present invention encompasses substituted 4-oxo-naphthyridine-3-carboxamides I or the pharmaceutically acceptable nontoxic salts of I (X = H, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl). I are highly selective agonists, antagonists or inverse agonists for **GABA<sub>A</sub>** brain receptors or prodrugs of agonists, antagonists or inverse agonists for **GABA<sub>A</sub>** brain receptors. I are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

ST oxonaphthyridinecarboxamide prepn **GABA** brain receptor ligand

IT **GABA** agonists

**GABA** antagonists

(**GABA<sub>A</sub>**; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as **GABA** brain receptor ligands)

IT Sleep

(disorder; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides in treatment of)

IT Amides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(naphthyridine-3-carboxamides; prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as **GABA** brain receptor ligands)

IT Anxiety

Down's syndrome

Seizures

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides in treatment

of)

IT 100961-91-9P  
 RL: BYP (Byproduct); PREP (Preparation)  
 (formation in prepn. of substituted 4-oxo-naphthyridine-3-carboxamides  
 as agonists, antagonists or inverse agonists for **GABAA** brain  
 receptors)

IT 220860-38-8P 220860-41-3P 220860-42-4P 220860-43-5P  
 220860-44-6P 220860-45-7P 220860-46-8P  
 220860-47-9P 220860-48-0P 220860-49-1P  
 220860-50-4P 220860-51-5P 220860-53-7P 220860-54-8P  
 220860-55-9P 220860-56-0P 220860-57-1P 220860-58-2P  
 220860-59-3P 220860-60-6P 220860-61-7P  
 220860-62-8P 220860-63-9P 220860-64-0P  
 220860-65-1P 220860-66-2P 220860-67-3P  
 220860-68-4P 220860-69-5P 220860-70-8P 220860-71-9P  
 220860-72-0P 220860-73-1P 220860-74-2P  
 220860-75-3P 220860-76-4P 220860-77-5P 220860-78-6P  
 220860-79-7P 220860-80-0P 220860-81-1P 220860-82-2P  
 220860-83-3P 220860-84-4P 220860-85-5P 220860-86-6P 220860-87-7P  
 220860-88-8P 220860-89-9P 220860-91-3P 220860-92-4P  
 220860-93-5P 220860-94-6P 220860-95-7P 220860-98-0P  
 220860-99-1P 220861-00-7P 220861-01-8P 220861-02-9P 220861-03-0P  
 220861-08-5P 220861-09-6P 220861-10-9P 220861-11-0P 220861-13-2P  
 220861-14-3P 220861-15-4P 220861-16-5P 220861-19-8P 220861-21-2P  
 220861-22-3P 220861-25-6P 220861-26-7P 304680-78-2P  
 304680-79-3P 304680-80-6P 304680-81-7P 304680-82-8P  
 304680-83-9P 304680-84-0P 304680-85-1P 304680-86-2P 304680-87-3P  
 304680-88-4P 304680-89-5P 304680-90-8P 304680-91-9P 304680-92-0P  
 304680-93-1P 304680-94-2P 304680-95-3P 304680-96-4P 304680-97-5P  
 304680-98-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists,  
 antagonists or inverse agonists for **GABAA** brain receptors)

IT 64-17-5, Ethanol, reactions 87-13-8, Diethyl ethoxymethylenemalonate  
 100-46-9, Benzylamine, reactions 109-73-9, Butylamine, reactions  
 4548-45-2, 2-Chloro-5-nitropyridine 17201-43-3, .alpha.-Bromo-p-  
 tolunitrile 24424-99-5, Di-tert-butyl dicarbonate 54303-30-9,  
 2-(Ethylthio)ethylamine hydrochloride 220861-33-6 220861-34-7  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant for prepn. of substituted 4-oxo-naphthyridine-3-carboxamides  
 as agonists, antagonists or inverse agonists for **GABAA** brain  
 receptors)

IT 2393-23-9P, 4-Methoxybenzylamine 21626-41-5P, 2-Benzylamino-5-  
 nitropyridine 21630-48-8P 31594-45-3P, 2-Ethoxy-5-nitropyridine  
 34403-48-0P 52025-34-0P, 2-Ethoxy-5-aminopyridine 92808-09-8P  
 92808-14-5P 92808-33-8P 220861-28-9P 220861-29-0P 220861-31-4P  
 304680-99-7P 304681-00-3P 304681-01-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (reactant for prepn. of substituted 4-oxo-naphthyridine-3-carboxamides  
 as agonists, antagonists or inverse agonists for **GABAA** brain  
 receptors)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; DE 2322750 1973 HCAPLUS
- (2) Anon; DE 2407744 1974 HCAPLUS
- (3) Anon; DE 279875 A1 1990
- (4) Anon; DE 279887 A1 1990
- (5) Anon; DE 295360 A5 1991
- (6) Geoffrey, W; Molecular Neuroscience, NeuroReport 1995, V6, P1313
- (7) Haskell; US 4374138 1983 HCAPLUS

- (8) Heindl, J; Eur J Med Chem 1977, V6, P549  
 (9) Kondo, K; Patent Abstracts of Japan 1999, V13(260)  
 (10) Laruelle; US 4621088 1986 HCAPLUS  
 (11) Murakami; US 3953428 1976 HCAPLUS  
 (12) Nuebling; US 5378679 1995 HCAPLUS  
 (13) White, G; Receptors and Channels 1995, V3, P1 HCAPLUS

L48 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS

AN 1999:166616 HCAPLUS

DN 130:196645

TI Preparation of 4-oxonaphthyridine-3-carboxamides as GABA brain receptor ligands

IN Albaugh, Pamela; Desimone, Robert W.; Liu, Gang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D471-04

ICS A61K031-44; C07D471-04; C07D221-00; C07D221-00


CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910347	A1	19990304	WO 1998-US17513	19980824
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2301599	AA	19990304	CA 1998-2301599	19980824
	AU 9891173	A1	19990316	AU 1998-91173	19980824
	AU 753800	B2	20021031		
	EP 1007526	A1	20000614	EP 1998-943352	19980824
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9811362	A	20000822	BR 1998-11362	19980824
	SI 20270	C	20001231	SI 1998-20055	19980824
	JP 2001514181	T2	20010911	JP 2000-507675	19980824
	MX 200001598	A	20001026	MX 2000-1598	20000215
	NO 2000000822	A	20000413	NO 2000-822	20000218
	BG 104192	A	20010531	BG 2000-104192	20000225
	LV 12539	B	20010120	LV 2000-29	20000316
PRAI	US 1997-918180	A	19970825		
	WO 1998-US17513	W	19980824		
OS	MARPAT 130:196645				
GI					





- AB The title compds. I [X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl] are prepd. I are highly selective agonists, antagonists or inverse agonists for **GABA<sub>A</sub>** brain receptors or prodrugs of agonists, antagonists or inverse agonists for **GABA<sub>A</sub>** brain receptors. These compds. are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness. In in vitro assays for **GABA<sub>A</sub>** receptor activity using rat cortical tissue homogenate and 3H-Flumazenil and diazepam, compds. of this invention showed  $K_i$  values of less than 1  $\mu$ M.
- ST oxonaphthyridinecarboxamide prepn **GABA** brain receptor ligand; **GABA** brain receptor ligand oxonaphthyridinecarboxamide prepn; anxiolytic oxonaphthyridinecarboxamide prepn; anticonvulsant oxonaphthyridinecarboxamide prepn; benzodiazepine overdose treatment oxonaphthyridinecarboxamide prepn; Down syndrome treatment oxonaphthyridinecarboxamide prepn
- IT **GABA** receptors  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (**GABA<sub>A</sub>**; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT Mental activity  
 (alertness; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on alertness)
- IT Mental disorder  
 (cognitive; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on cognitive disorders)
- IT Cognition  
 (disorder; prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on cognitive disorders)
- IT Anticonvulsants  
 Anxiolytics  
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT **GABA** receptors  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands)
- IT Down's syndrome  
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on Down syndrome)
- IT Sleep  
 (prepn. of oxonaphthyridinecarboxamides as **GABA** brain receptor ligands with effect on sleep)
- IT 220860-38-8P 220860-40-2P 220860-41-3P 220860-42-4P  
 220860-43-5P 220860-44-6P 220860-45-7P  
 220860-46-8P 220860-47-9P 220860-48-0P 220860-49-1P  
 220860-50-4P 220860-51-5P 220860-52-6P 220860-53-7P  
 220860-54-8P 220860-55-9P 220860-56-0P 220860-57-1P

220860-58-2P 220860-59-3P 220860-60-6P  
 220860-61-7P 220860-62-8P 220860-63-9P 220860-64-0P  
 220860-65-1P 220860-66-2P 220860-67-3P  
 220860-68-4P 220860-69-5P 220860-70-8P 220860-71-9P  
 220860-72-0P 220860-73-1P 220860-74-2P  
 220860-75-3P 220860-76-4P 220860-77-5P 220860-78-6P  
 220860-79-7P 220860-80-0P 220860-81-1P 220860-82-2P  
 220860-83-3P 220860-84-4P 220860-85-5P 220860-86-6P 220860-87-7P  
 220860-88-8P 220860-89-9P 220860-90-2P 220860-91-3P  
 220860-92-4P 220860-93-5P 220860-94-6P  
 220860-95-7P 220860-96-8P 220860-97-9P 220860-98-0P  
 220860-99-1P 220861-00-7P 220861-01-8P 220861-02-9P 220861-03-0P  
 220861-04-1P 220861-05-2P 220861-06-3P 220861-07-4P 220861-08-5P  
 220861-09-6P 220861-10-9P 220861-11-0P 220861-12-1P 220861-13-2P  
 220861-14-3P 220861-15-4P 220861-16-5P 220861-17-6P  
 220861-18-7P 220861-19-8P 220861-20-1P 220861-21-2P 220861-22-3P  
 220861-23-4P 220861-25-6P 220861-26-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 17658-19-4P

RL: BYP (Byproduct); PREP (Preparation)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 64-17-5, Ethanol, reactions 74-89-5, Methylamine, reactions 87-13-8, Diethyl ethoxymethylenemalonate 100-46-9, Benzylamine, reactions 108-00-9, N,N-Dimethylethylenediamine 109-73-9, 1-Butanamine, reactions 541-41-3, Ethyl chloroformate 2393-23-9, 4-Methoxybenzylamine 4548-45-2, 2-Chloro-5-nitropyridine 17201-43-3, .alpha.-Bromo-p-tolunitrile 24424-99-5, Di-tert-butyl dicarbonate 54303-30-9 92808-14-5 220861-33-6 220861-34-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

IT 21626-41-5P 21630-48-8P 31594-45-3P 34403-48-0P 52025-34-0P  
 92808-09-8P 92808-33-8P 191871-90-6P 220861-27-8P 220861-28-9P  
 220861-29-0P 220861-30-3P 220861-31-4P 220861-32-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of oxonaphthyridinecarboxamides as GABA brain receptor ligands)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Allen & Hanburys; DE 2407744 A 1974 HCAPLUS
- (2) Haskell, T; US 4374138 A 1983 HCAPLUS
- (3) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 279875 A 1990 HCAPLUS
- (4) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 279887 A 1990 HCAPLUS
- (5) Institut Fur Wirkstoffforschung Der Akademie Der Wissenschaften; DD 295360 A 1991 HCAPLUS
- (6) Otsuka Pharmaceut Co Ltd; JP 01061461 A 1989 HCAPLUS
- (7) Yamanouchi Pharmaceutical Co Ltd; DE 2322750 A 1973 HCAPLUS

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 16:09:40 ON 29 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:09:40 ON 29 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 141

L49 5 L41

=> d bib abs hitrn tot

L49 ANSWER 1 OF 5 USPATFULL

AN 2002:337995 USPATFULL

TI Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders

IN Villalobos, Anabella, Niantic, CT, UNITED STATES

PI US 2002193360 A1 20021219

AI US 2002-83743 A1 20020226 (10)

PRAI US 2001-272566P 20010301 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1737

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a GABA.sub.A inverse agonist or a pharmaceutically acceptable salt thereof; and a nicotine receptor partial agonist, an estrogenic agent, selective estrogen receptor modulator or vitamin E or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The GABA.sub.A inverse agonist, and nicotine receptor partial agonist, estrogen, selective estrogen receptor modulator or vitamin E are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease, Huntington's disease, memory impairment associated with depression or anxiety, schizophrenia, Down's syndrome, stroke, traumatic brain injury (TBI), AIDS associated dementia and attention deficit disorder. The method of using these compositions is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-40-2 220860-45-7 220860-47-9

220860-48-0 220860-50-4 220860-52-6

220860-56-0 220860-58-2 220860-59-3

220860-60-6 220860-62-8 220860-64-0

220860-65-1 220860-66-2 220860-67-3

220860-68-4 220860-70-8 220860-72-0

220860-74-2 220860-75-3 220860-81-1

220860-90-2 220860-92-4 220860-93-5

220860-95-7 220861-17-6 304680-79-3

415678-14-7 415678-15-8

(use of GABAA inverse agonists in combination with nicotine receptor partial agonists or estrogen or selective estrogen modulators or vitamin E for treatment of cognitive disorders)

L49 ANSWER 2 OF 5 USPATFULL

AN 2002:280830 USPATFULL

TI Substituted 4-oxo-naphthyridine-3-carboxamides: GABA brain receptor ligands

IN Albaugh, Pamela A., Carmel, IN, UNITED STATES

DeSimone, Robert W., Durham, CT, UNITED STATES

Liu, Gang, Oak Park, CA, UNITED STATES

PA Neurogen Corporation, Corporation of the State of Delaware, Branford, CT  
(U.S. corporation)  
PI US 2002156280 A1 20021024  
AI US 2002-114743 A1 20020402 (10)  
RLI Continuation of Ser. No. US 2000-634093, filed on 8 Aug 2000, GRANTED,  
Pat. No. US 6399604 Continuation of Ser. No. US 1998-139456, filed on 25  
Aug 1998, GRANTED, Pat. No. US 6143760  
PRAI US 1997-56799P 19970825 (60)  
DT Utility  
FS APPLICATION  
LREP Steven J. Sarussi, McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300  
S. Wacker Drive, Chicago, IL, 60606  
CLMN Number of Claims: 106  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1878  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention encompasses structures of the Formula ##STR1##

or the pharmaceutically acceptable non-toxic salts thereof wherein:

X is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or  
amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl,

which compounds are highly selective agonists, antagonists or inverse  
agonists for GABAA brain receptors or prodrugs of agonists, antagonists  
or inverse agonists for GABAA brain receptors. These compounds are  
useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep,  
cognitive and seizure disorders, and overdose with benzodiazepine drugs  
and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P  
220860-47-9P 220860-48-0P 220860-50-4P  
220860-56-0P 220860-58-2P 220860-59-3P  
220860-60-6P 220860-62-8P 220860-64-0P  
220860-65-1P 220860-66-2P 220860-67-3P  
220860-68-4P 220860-70-8P 220860-72-0P  
220860-74-2P 220860-75-3P 220860-81-1P  
220860-92-4P 220860-93-5P 220860-95-7P  
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists,  
antagonists or inverse agonists for GABAA brain receptors)

L49 ANSWER 3 OF 5 USPATFULL

AN 2002:273463 USPATFULL

TI Combination use of acetylcholinesterase inhibitors and GABAA inverse  
agonists for the treatment of cognitive disorders

IN Villalobos, Anabella, Niantic, CT, UNITED STATES

Cassella, James V., Guilford, CT, UNITED STATES

Rajachandran, Lavanya, Wallingford, CT, UNITED STATES

PI US 2002151591 A1 20021017

AI US 2001-976347 A1 20011012 (9)

PRAI US 2000-241145P 20001017 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,  
10017-5612

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 1102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a composition for treating a cognitive disorder, which comprises an acetylcholinesterase inhibitor, and a GABA.sub.A inverse agonist selected from a compound of the formula. ##STR1##

where X and Y are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-40-2 220860-45-7 220860-47-9

220860-48-0 220860-50-4 220860-52-6

220860-56-0 220860-58-2 220860-59-3

220860-60-6 220860-62-8 220860-64-0

220860-65-1 220860-66-2 220860-67-3

220860-68-4 220860-70-8 220860-72-0

220860-74-2 220860-75-3 220860-81-1

220860-90-2 220860-92-4 220860-93-5

220860-95-7 220861-17-6 304680-79-3

415678-14-7 415678-15-8

(combination of acetylcholinesterase inhibitors and GABAA inverse agonists for treatment of cognitive disorders)

L49 ANSWER 4 OF 5 USPATFULL

AN 2002:129963 USPATFULL

TI Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands

IN Albaugh, Pamela A., Clinton, CT, United States

DeSimone, Robert W., Durham, CT, United States

Liu, Gang, Agoura, CA, United States

PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)

PI US 6399604 B1 20020604

AI US 2000-634093 20000808 (9)

RLI Continuation of Ser. No. US 1998-139456, filed on 25 Aug 1998, now patented, Pat. No. US 6143760

PRAI US 1997-56799P 19970825 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Seaman, D. Margaret

LREP McDonnell Boehnen Hulbert & Berghoff

CLMN Number of Claims: 107

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses structures of the Formula ##STR1##

or the pharmaceutically acceptable non-toxic salts thereof wherein:

X is hydrogen, halogen; (un)substituted alkyl, (un)substituted alkoxy or amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P

220860-47-9P 220860-48-0P 220860-50-4P

220860-56-0P 220860-58-2P 220860-59-3P

220860-60-6P 220860-62-8P 220860-64-0P  
220860-65-1P 220860-66-2P 220860-67-3P  
220860-68-4P 220860-70-8P 220860-72-0P  
220860-74-2P 220860-75-3P 220860-81-1P  
220860-92-4P 220860-93-5P 220860-95-7P  
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors)

L49 ANSWER 5 OF 5 USPTFLL  
AN 2000:150180 USPTFLL  
TI Substituted 4-oxo-naphthyridine-3-carboxamides: GABA brain receptor ligands  
IN Albaugh, Pamela A., Clinton, CT, United States  
DeSimone, Robert W., Durham, CT, United States  
Liu, Gang, Agoura, CA, United States  
PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)  
PI US 6143760 20001107  
AI US 1998-139456 19980825 (9)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Seaman, D. Margaret  
LREP McDonnell Boenn Hulbert & Berghoff, Sarussi, Steven J.  
CLMN Number of Claims: 110  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses structures of the Formula ##STR1## or the pharmaceutically acceptable non-toxic salts thereof wherein: x is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and

Y is (un)substituted alkyl, aryl, or heteroaryl,

which compounds are highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220860-43-5P 220860-44-6P 220860-45-7P  
220860-47-9P 220860-48-0P 220860-50-4P  
220860-56-0P 220860-58-2P 220860-59-3P  
220860-60-6P 220860-62-8P 220860-64-0P  
220860-65-1P 220860-66-2P 220860-67-3P  
220860-68-4P 220860-70-8P 220860-72-0P  
220860-74-2P 220860-75-3P 220860-81-1P  
220860-92-4P 220860-93-5P 220860-95-7P  
304680-79-3P

(prepn. of substituted 4-oxo-naphthyridine-3-carboxamides as agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 120014-06-4 REGISTRY

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-E 2020

CN Donepezil

FS 3D CONCORD

DR 142057-79-2

MF C24 H29 N O3


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MRCK\*, MSDS-OHS, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

225 REFERENCES IN FILE CA (1957 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

226 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=>